AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The primary goal of AMAG and its maternal health division, Lumara Health, is to bring to market therapies that provide clear benefits and improve patients' lives. In addition to continuing to pursue opportunities to make new advancements in patients' health and to enhance treatment accessibility, AMAG intends to continue to expand and diversify its portfolio through the in-license or purchase of additional pharmaceutical products or companies.
Waltham, US
Size (employees)
545 (est)-1%
AMAG Pharmaceuticals was founded in 1981 and is headquartered in Waltham, US

AMAG Pharmaceuticals Office Locations

AMAG Pharmaceuticals has an office in Waltham
Waltham, US (HQ)
1100 Winter St

AMAG Pharmaceuticals Metrics

AMAG Pharmaceuticals Financial Metrics

Revenue (2016)

$532.1 m

Revenue growth (2015-16), %


Gross profit

$511.5 m

Gross profit margin (2016), %


Net income (2016)

($2.5 m)

Market capitalization (21-Mar-2017)

$734.9 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$274.3 m
AMAG Pharmaceuticals's current market capitalization is $734.9 m.
AMAG Pharmaceuticals's revenue was reported to be $532.1 m in FY, 2016 which is a 27.2% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$80.9 m$124.4 m$418.3 m$532.1 m

Revenue growth, %


Cost of goods sold

$12 m$20.3 m$10 m$20.6 m

Gross profit

$68.9 m$104.1 m$408.3 m$511.5 m

Gross profit Margin, %


Operating expense total

$80.5 m$107.9 m$297.1 m$453.2 m


($7.6 m)($3.8 m)$111.2 m$78.9 m

EBIT margin, %


Interest expense

($14.7 m)($53.3 m)($73.2 m)

Interest income

$3.1 m

Pre tax profit

($9.6 m)$9.1 m

Income tax expense

$153.2 m$7.1 m$11.5 m

Net Income

($9.6 m)$135.8 m$32.8 m($2.5 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$27 m$119.3 m$228.7 m$274.3 m

Accounts Receivable

$6.8 m$38.2 m$85.7 m$92.4 m


$17.2 m$40.6 m$40.6 m$37.3 m

Current Assets

$244.4 m$274 m$606.7 m$718.6 m


$1.8 m$1.5 m$28.7 m$24.5 m


$205.8 m$639.2 m$639.5 m

Total Assets

$265.5 m$1.4 b$2.5 b$2.5 b

Accounts Payable

$2.6 m$7.3 m$4.9 m$3.7 m

Current Liabilities

$33.1 m$166.5 m$245.9 m$312.9 m

Additional Paid-in Capital

$641.9 m$793.8 m$1.2 b$1.2 b

Retained Earnings

($466.3 m)($330.4 m)($297.7 m)($300.1 m)

Total Equity

$172.4 m$460 m$932.3 m$934.4 m

Financial Leverage

1.5 x3 x2.7 x2.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($9.6 m)$135.8 m$32.8 m($2.5 m)

Depreciation and Amortization

$3.1 m$7 m$69.1 m$99.9 m

Accounts Receivable

($432 k)$3.6 m($37 m)($9.9 m)


($1 m)($1.4 m)($5.2 m)($2.4 m)

Accounts Payable

($5.7 m)$10.7 m$7.9 m$49 m

Cash From Operating Activities

($6.8 m)$11.4 m$96 m$246.2 m

Capital Expenditures

($1.6 m)($147 k)($5.5 m)

Cash From Investing Activities

($13.9 m)($432.9 m)($899 m)($72.7 m)

Interest Paid

$28 m$62.4 m

Income Taxes Paid

$2.4 m$5.3 m

Free Cash Flow

($5.1 m)$11.6 m$251.7 m

AMAG Pharmaceuticals Market Value History

AMAG Pharmaceuticals Company Life

You may also be interested in